Literature DB >> 32952358

Association between Low-Grade Inflammation and Left Ventricular Diastolic Dysfunction in Patients with Metabolic Syndrome and Hyperuricemia.

Cheng-Wei Liu1,2,3, Jui-Hung Chen1, Guo-Shiang Tseng4, Ko-Hung Chen3,5, Juey-Jen Hwang3,6, Wei-Shiung Yang3, Yen-Wen Wu7,8,9.   

Abstract

BACKGROUND: Hyperuricemia (HUA) induces inflammation and insulin resistance and is reportedly associated with left ventricular hypertrophy (LVH) and possibly with left ventricular diastolic dysfunction (LVDD).
OBJECTIVES: To investigate associations among HUA, inflammation, and insulin resistance with LVDD.
METHODS: We enrolled patients with metabolic syndrome (MetS) between August 1, 2017, and December 31, 2017. All participants underwent fasting blood tests and transthoracic echocardiography. HUA was defined as an serum uric acid level ≥ 7 mg/dl in men or ≥ 6 mg/dl in women. MetS was defined as at least three of the following Taiwanese criteria: central obesity, prehypertension, fasting glucose impairment, hypertriglyceridemia, and lower values of high-density lipoprotein cholesterol. LVDD was defined according to contemporary guidelines.
RESULTS: The study included 63 patients (60% male) with a mean age of 53 ± 14 years and body mass index (BMI) of 29.4 ± 4.0 kg/m2. Prevalence rates of HUA, LVH, LVDD were 40%, 18%, and 10%, respectively. Baseline characteristics were similar between the HUA and normouricemia groups, except that the HUA group had significantly higher serum high-sensitivity interleukin 6 and tumor necrosis factor-alpha (TNF-α) levels. LVDD occurred more frequently in the HUA group (20.0% vs. 2.6%, p = 0.032). HUA was associated with LVDD [crude odds ratio (OR): 9.25, 95% confidence interval (CI): 1.01-84.7, p = 0.049]. In multivariate analysis, the most relevant factor associated with LVDD was TNF-α after adjustments for age, male sex, and body mass index (adjusted OR for TNF-α: 4.1, 95% CI: 1.02-16.5, p = 0.047).
CONCLUSIONS: The association between HUA and LVDD partially reflected a low-grade inflammation due to elevated TNF-α rather than increased insulin resistance in MetS patients.

Entities:  

Keywords:  Echocardiography; Hyperuricemia; Left ventricular diastolic dysfunction; Metabolic syndrome

Year:  2020        PMID: 32952358      PMCID: PMC7490613          DOI: 10.6515/ACS.202009_36(5).20200406A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  34 in total

1.  Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.

Authors:  Amil M Shah; Brian Claggett; Nancy K Sweitzer; Sanjiv J Shah; Inder S Anand; Eileen O'Meara; Akshay S Desai; John F Heitner; Guichu Li; James Fang; Jean Rouleau; Michael R Zile; Valetin Markov; Vyacheslav Ryabov; Gilmar Reis; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2014-08-13       Impact factor: 8.790

2.  Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population.

Authors:  Cesare Cuspidi; Rita Facchetti; Michele Bombelli; Carla Sala; Marijana Tadic; Guido Grassi; Giuseppe Mancia
Journal:  Am J Hypertens       Date:  2017-03-01       Impact factor: 2.689

3.  Combination of hyperuricemia and metabolic syndrome is an independent and powerful predictor for left ventricular hypertrophy in rural Chinese.

Authors:  Shasha Yu; Xiaofan Guo; Hongmei Yang; Yingxian Sun
Journal:  Ann Endocrinol (Paris)       Date:  2015-06-30       Impact factor: 2.478

4.  Hyperuricemia is an independent predictive factor for left ventricular diastolic dysfunction in patients with chronic kidney disease.

Authors:  Leszek Gromadziński; Beata Januszko-Giergielewicz; Piotr Pruszczyk
Journal:  Adv Clin Exp Med       Date:  2015 Jan-Feb       Impact factor: 1.727

5.  Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

Authors:  Kazuhide Ogino; Masahiko Kato; Yoshiyuki Furuse; Yoshiharu Kinugasa; Katsunori Ishida; Shuichi Osaki; Toru Kinugawa; Osamu Igawa; Ichiro Hisatome; Chiaki Shigemasa; Stefan D Anker; Wolfram Doehner
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

6.  Association and interaction analysis of metabolic syndrome and serum uric acid on diastolic heart failure.

Authors:  Z-H Tang; Z Fang; F Zeng; Z Li; L Zhou
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

Review 7.  Uric acid and cardiovascular risk.

Authors:  Daniel I Feig; Duk-Hee Kang; Richard J Johnson
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

8.  Hyperuricemia and the echocardiographic measures of myocardial dysfunction.

Authors:  Eswar Krishnan; Ali Hariri; Omar Dabbous; Bhavik J Pandya
Journal:  Congest Heart Fail       Date:  2011-10-31

Review 9.  Tumor necrosis factor-α antagonists: Side effects and their management.

Authors:  Sunil Dogra; Geeti Khullar
Journal:  Indian J Dermatol Venereol Leprol       Date:  2013-07       Impact factor: 2.545

10.  Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology.

Authors:  Brendan N Putko; Zuocheng Wang; Jennifer Lo; Todd Anderson; Harald Becher; Jason R B Dyck; Zamaneh Kassiri; Gavin Y Oudit
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.